Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.522
Peer-review started: October 20, 2019
First decision: November 13, 2019
Revised: December 9, 2019
Accepted: December 14, 2019
Article in press: December 14, 2019
Published online: February 6, 2020
Processing time: 108 Days and 11.7 Hours
Radiation recall dermatitis has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented.
Here, we report the rare occurrence of radiation recall dermatitis after palliative radiotherapy for bone metastases in a metastatic melanoma patient treated with a combination of dabrafenib and trametinib.
We present a case of radiation recall dermatitis after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib. This is a very rare toxic event, and there is insufficient data to describe prevention strategies. Increased awareness and reporting of cases will help to better explain the association between targeted therapy and the radiation recall phenomenon.
Core tip: Radiation recall dermatitis is a very rare toxic event. Here we report a case of this phenomenon after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib.